Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials

Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma 

Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication

New FDA Commissioner Confirmed

Dr. Richard Pazdur Discusses Project Facilitate and the Expanded-Access Program

NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During Social Media Event

FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur

NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors

NCI Selects Five Teams of Researchers to Expand Discovery of Predictive Biomarkers for Immunotherapy

The Budget Landscape with Dr. Douglas R. Lowy

FDA Fosters Understanding about Approval Process for Biosimilars

The Upcoming Lung Cancer Neoadjuvant Meeting